EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown significant success treating NSCLC patients harboring activating EGFR mutations (27), yet patients who initially show good response often develop resistance through various mechanisms. Here, EGFR is linked to non-small cell lung carcinoma.